Figure 2. Left ventricular dysfunction (LVD)-free survival according to the body mass index (BMI) (A) and use of trastuzumab (B) on Kaplan-Meier curve analysis. (A) LVD-free survival rate was significant higher in patients with higher BMI than those with lower BMI. (B) LVD-free survival rate was significant higher in patients without expose to trastuzumab than those treated with trastuzumab.
